New Mexico Educational Retirement Board Takes Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

New Mexico Educational Retirement Board purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 69,300 shares of the company's stock, valued at approximately $733,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. nVerses Capital LLC acquired a new stake in Roivant Sciences in the 2nd quarter worth approximately $34,000. DNB Asset Management AS lifted its stake in shares of Roivant Sciences by 6.4% during the second quarter. DNB Asset Management AS now owns 56,022 shares of the company's stock worth $592,000 after buying an additional 3,386 shares during the period. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Roivant Sciences by 26.7% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 18,742 shares of the company's stock valued at $210,000 after buying an additional 3,955 shares during the last quarter. Dynamic Technology Lab Private Ltd increased its position in shares of Roivant Sciences by 35.1% in the 4th quarter. Dynamic Technology Lab Private Ltd now owns 17,155 shares of the company's stock valued at $193,000 after acquiring an additional 4,458 shares during the period. Finally, Covestor Ltd raised its stake in Roivant Sciences by 22.9% in the 1st quarter. Covestor Ltd now owns 25,178 shares of the company's stock worth $265,000 after acquiring an additional 4,684 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently commented on ROIV. Piper Sandler upped their target price on Roivant Sciences from $20.00 to $22.00 and gave the company an "overweight" rating in a research report on Wednesday, July 10th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Roivant Sciences in a research note on Tuesday, June 18th. Finally, HC Wainwright restated a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Monday, August 19th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $17.10.

Roivant Sciences Price Performance

NASDAQ ROIV traded up $0.11 on Friday, hitting $12.30. The company had a trading volume of 5,071,029 shares, compared to its average volume of 5,642,814. The company has a debt-to-equity ratio of 0.05, a current ratio of 27.91 and a quick ratio of 27.91. The company's fifty day moving average price is $11.21 and its 200-day moving average price is $11.02. The company has a market capitalization of $9.09 billion, a PE ratio of 2.43 and a beta of 1.25. Roivant Sciences Ltd. has a 12-month low of $8.24 and a 12-month high of $13.24.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The firm had revenue of $55.10 million during the quarter, compared to the consensus estimate of $30.72 million. During the same quarter in the prior year, the firm earned ($0.38) EPS. The company's revenue for the quarter was up 155.1% on a year-over-year basis. As a group, analysts predict that Roivant Sciences Ltd. will post -1.14 earnings per share for the current year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.